New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2012
06:58 EDTABTAbbott Chinese infant formula violates China National Standards, CER reports
An infant formula product produced by Abbott Laboratories, failed to reach China national safety standards and tested worst among a selection of six infant formula powders sold on the Chinese market, according to a research report released by Hong Kong-based research house CER Research. The release of the research report on Abbott's Similac Stage 1 milk powder product coincided with Chinese media reports Wednesday of a father in the China city of Hangzhou who says he had found half of a condom inside an Abbott milk powder package which he had purchased for his daughter. Abbott's total mainland China revenues for 2011 are estimated to have been between $0.95B-$1.10B, based on CER Research's investigations. CER Research said it had submitted the test results and report findings to the relevant food quality assessment government organizations in Shanghai and Guangdong province the Shanghai Municipal Bureau of Quality and Technical Supervision and the Administration of Quality and Technology Supervision of Guangdong Province. Both confirmed receipt and said they are looking into the case. The poor performance of the Abbott infant formula product was confirmed in additional testing performed by DTS Food Laboratories in Kensington, Australia. Reference Link
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ABT news | >>
July 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:40 EDTABTEarnings Preview: Abbott targets continued gains in emerging markets
Subscribe for More Information
11:13 EDTABTPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:15 EDTABTAbbott unit sale to Mylan 'a wash,' says Citigroup
Subscribe for More Information
July 14, 2014
16:30 EDTABTOn The Fly: Closing Wrap
Subscribe for More Information
12:21 EDTABTOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTABTAbbott CEO aims to boost medical device line, Reuters says
Subscribe for More Information
09:16 EDTABTOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:55 EDTABTMylan says does not anticipate regulatory hurdles prohibiting close of deal
08:49 EDTABTMylan says Abbott assets unlike other mature generic drug portfolios
Subscribe for More Information
08:36 EDTABTMylan accretive tax inversion deal makes sense, says UBS
Subscribe for More Information
08:27 EDTABTMylan sees Abbott transaction to be 'immediately and significantly accretive'
Subscribe for More Information
08:26 EDTABTMylan sees $10B in pro forma 2014 sales after closing Abbott deal
Subscribe for More Information
08:12 EDTABTMylan says Abbott deal 'first in series' of planned transactions
Subscribe for More Information
07:28 EDTABTMylan to host conference call
Subscribe for More Information
07:20 EDTABTAbbott to host conference call
Conference call to discuss agreement to sell developed markets branded generics pharmaceuticals business to Mylan will be held on July 14 at 9:30 am. Webcast Link
06:33 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:33 EDTABTMylan to acquire Abbott assets in all-stock transaction valued at about $5.3B
Subscribe for More Information
06:31 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
July 13, 2014
20:22 EDTABTMylan near buying Europe-based drug portfolio from Abbott, Reuters says
Subscribe for More Information
1 | 2 | all recent ABT news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use